Conrad Wai, CEO of Counterpart Health and an officer of Clover Health Investments, Corp. /DE (NASDAQ:CLOV), filed a Form 4 on September 16, 2026, disclosing the sale of 300,000 shares of Class A Common Stock on September 15, 2026, under a pre-established Rule 10b5-1 trading plan.
Key Highlights
- Shares sold: 300,000 shares of Class A Common Stock disposed of on 09/15/2026
- Weighted average price: $4.72 per share, with individual transactions ranging from $4.60 to $5.06
- Trading plan: Sale executed pursuant to a Rule 10b5-1 plan adopted by Conrad Wai on June 8, 2026
- Remaining indirect holdings: 1,170,056 shares held indirectly through a family trust, of which the reporting person is a co-trustee
- Direct holdings: 1,065,699 shares of Class A Common Stock held directly following the transaction
- Reporting person role: Conrad Wai is identified as CEO, Counterpart Health, and an officer of the issuer
Clover Health Officer Conrad Wai Reports Share Disposition Under Pre-Planned Sale Agreement
According to the filing, Conrad Wai, serving as CEO of Counterpart Health and an officer of Clover Health Investments, Corp. /DE, disposed of 300,000 shares of Class A Common Stock on September 15, 2026. The transaction was coded "S" in Table I of the Form 4, indicating a sale. The filing discloses that the reported price of $4.72 is a weighted average, and that the shares were sold across multiple transactions at prices ranging from $4.60 to $5.06, inclusive. The filing notes that Wai undertakes to provide full details of shares sold at each separate price upon request from the SEC staff, the issuer, or any security holder.
The sale was carried out under a Rule 10b5-1 trading plan that Wai adopted on June 8, 2026, as indicated in the filing's footnote and confirmed by the checkbox on the form indicating the transaction was "made pursuant to a contract, instruction or written plan" intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Following the reported transaction, the filing discloses that Wai beneficially owns 1,170,056 shares indirectly through a trust described as held "for the benefit of the Reporting Person's family, of which the Reporting Person is a co-trustee," and 1,065,699 shares held directly. The Form 4 was signed by Peter J. Rivas as attorney-in-fact for Conrad Wai and filed on September 16, 2026.
What Was Disclosed
The filing reports a single open-market sale of 300,000 Class A Common Stock shares by a Clover Health Investments, Corp. /DE officer at a weighted average price of $4.72, executed under a pre-established 10b5-1 plan, with combined post-transaction beneficial ownership of 2,235,755 shares across direct and indirect holdings.



Please wait processing your request...